Biosen-Assisted Growth-Coupled Evolutionary Pressure on Epimerase for Improved D-Allulose Biosynthesis

Better Enzymes Start With Better Screening

D-allulose enzymes have a boring problem. They don’t stay active long enough or convert fructose fast enough. This study gives enzyme engineers a smarter way to find mutants that fix both issues. The tool is a biosensor that raises the bar automatically. No heroics required.

Why KEases Are the Bottleneck

D-allulose production usually depends on ketose 3-epimerases, or KEases. These enzymes convert D-fructose into D-allulose. That step is clean, but the enzyme itself often limits the process. Natural KEases can be too slow, too fragile, or both.

Traditional protein engineering tackles this by making random mutations and testing one variant at a time. That is slow. The researchers behind this paper wanted to let the cells do the screening instead.

What the Study Did

The team built a D-allulose-dependent biosensor, referred to as Biosen. The biosensor creates a direct link between cell growth and D-allulose production. A cell only grows well if its enzyme makes D-allulose. More D-allulose means faster growth. Less D-allulose means the cell loses the race.

That setup creates real evolutionary pressure. Instead of measuring each mutant manually, the culture itself enriches for the best performers. The authors applied this growth-coupled in vivo screening platform to a ketose 3-epimerase called ADAE. After rounds of evolution, they isolated the M42 mutant.

What the Numbers Show

The M42 mutant is a meaningful step forward.

Metric	Result for M42 relative to starting ADAE
Catalytic activity	6.28-fold higher
Half-life at 60°C	2.5-fold longer
D-allulose yield from D-fructose in 3 hours	32.2%

Those numbers matter together, not just separately. A faster enzyme is useful. A more stable enzyme is useful. A faster and more stable enzyme changes production economics.

The 32.2% conversion is especially relevant. That happened in three hours from D-fructose. For a low-calorie sweetener produced at scale, temperature tolerance and yield are exactly the metrics formulators and buyers should watch.

What This Means for Formulators and Buyers

For formulators, this type of work points to a more dependable enzyme supply. A longer half-life at 60°C matters in large reactors. Heat degrades enzymes over time. If the catalyst keeps working through longer batches, the process becomes more predictable.

For ingredient buyers, the implications are simpler. Higher catalytic activity lowers enzyme loading. Better stability lowers downtime. Higher conversion lowers downstream purification costs. All three affect the final price of D-allulose.

The screening platform itself may be the bigger story. Biosen is not limited to this one epimerase. The same growth-coupled logic can be applied to other rare sugar enzymes and other biocatalytic steps. That broadens the pipeline for commercial ingredients.

Questions Formulators and Buyers Ask

Can I use the M42 mutant in a food-grade process today?

Not yet. This is a laboratory result. The data look strong, but scale-up and food-grade formulation have not been shown. M42 is a serious candidate, not a commercial product.

How does growth-coupled screening differ from conventional screening?

Conventional screening tests each variant. Growth-coupled screening creates a situation where only the best producers survive. The selection step becomes automatic. That speeds up development and lets researchers examine far more variants.

Will this make D-allulose cheaper?

It can help. Enzyme cost and conversion yield are central to D-allulose production. A 6.28-fold activity increase and a 2.5-fold stability improvement directly attack those cost drivers. Better catalysts usually lead to better wholesale pricing.

The Practical Outlook

Watch for follow-up work on M42. Also watch for the screening method itself. The biosensor approach gives enzyme engineers a way to optimize for real process conditions, not just idealized lab assays. For buyers, that means D-allulose has a clearer path to cost stability. For formulators, it means the enzyme supply behind the sweetener is only going to get more efficient. That is worth tracking.